Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8019320 | 0.89 | TSHR (0.48) | TSHRLMNATYRKIF11ALDH1A1 | |
| SCHEMBL424728 | 0.83 | TSHR (0.73) | TSHRLMNATYRKIF11ALDH1A1 | |
| SCHEMBL11209484 | 0.81 | TSHR (0.55) | TSHRLMNATYRKIF11ALDH1A1 | |
| SCHEMBL13704994 | 0.81 | TSHR (0.55) | TSHRLMNATYRKIF11ALDH1A1 | |
| Hydrogen Peroxide SCHEMBL28677809 | 0.76 | LMNA (0.71) | TSHRLMNATYRKIF11ALDH1A1 | |
| SCHEMBL11527250 | 0.75 | TSHR (0.55) | TSHRLMNAALDH1A1HPGDNPC1 | |
| SCHEMBL8889645 | 0.75 | TSHR (0.55) | TSHRLMNATYRKIF11ALDH1A1 | |
| SCHEMBL11588689 | 0.75 | TSHR (0.55) | TSHRLMNAALDH1A1HPGDNPC1 | |
| SCHEMBL197202 | 0.75 | MEN1 (0.62) | TSHRLMNATYRKIF11ALDH1A1 | |
| SCHEMBL26915 | 0.73 | KIF11 (0.70) | TSHRLMNATYRKIF11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115784905-B | Fluorene derivative and application thereof | 北京八亿时空液晶科技股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-111689995-B | High-solubility triaryl carbon borate and preparation method and application thereof | 万华化学集团股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-115784905-A | Fluorene derivative and application thereof | 北京八亿时空液晶科技股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-8003628-B2 | Methods of inhibiting osteoclast activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090306030-A1 | Methods Of Inhibiting Osteoclast Activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-12-10 | — | — | US | disclosed |
| US-7566741-B2 | Methods of inhibiting osteoclast activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566741-B2 | Methods of inhibiting osteoclast activity | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2009-07-28 | — | — | US | disclosed |
| EP-0741741-B1 | MODIFIED OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 2002-08-28 | — | — | EP | disclosed |
| US-6066447-A | INCLUDING NUCLEOSIDE DIMERS WITH MODIFIED BACKBONES; FOR VIRICIDES AND ANTISENSE AGENTS | NOVARTIS CORPORATION (US) | 2000-05-23 | — | — | US | disclosed |
| EP-0741741-A1 | MODIFIED OLIGONUCLEOTIDES | Novartis AG (CH) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020597-A1 | MODIFIED OLIGONUCLEOTIDES | CIBA-GEIGY AG (CH) | 1995-08-03 | — | — | WO | disclosed |
| US-4171426-A | ANIONIC CATALYST, 2-PYRROLIDONE OR E-CAPROLACTAM | CHEVRON RESEARCH COMPANY (US) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306030-A1 | Methods Of Inhibiting Osteoclast Activity | NFATC1, CD40LG, CD14 | TSHR 753/4885LMNA 1103/4885TYR 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.